

INFORMAȚII PERSONALE
TOMULEASA CIPRIAN

Locul de muncă vizat / Domeniul ocupațional	<p>Expert implementare proiect Dezvoltarea de instrumente de lucru specifice și programe de instruire pentru consolidarea rețelei naționale de centre de expertiză în boli rare, în vederea creșterii capacității de îngrijire integrată a pacienților – ExpertRARE, cod SMIS 348253</p> <p>Medic cu formare clinică în specialitatea Genetică Medicală cadrul Spitalul Clinic de Urgență pentru Copii „Louis Turcanu”, Timișoara – unitate de referință națională pentru patologii rare – și implicare în evaluarea și monitorizarea pacienților cu boli genetice complexe. Am fost implicată în evaluarea, diagnosticul și managementul pacienților cu patologii genetice și multisistemice rare, într-un cadru multidisciplinar și în alte proiecte vizând bolile rare.</p>
--	---

EXPERIENȚA PROFESIONALĂ

2022 – PREZENT	<p>MEDIC PRIMAR HEMATOLOG INSTITUTUL ONCOLOGIC ION CHIRICUȚĂ, CLUJ-NAPOCA, ROMÂNIA</p>
2022 – PREZENT	<p>CONFERENȚIAR UNIVERSITAR – DEPARTAMENTUL DE HEMATOLOGIE UNIVERSITATEA DE MEDICINA SI FARMACIE „IULIU HAȚIEGANU” CLUJ NAPOCA</p>
2021 – PREZENT	<p>SECRETAR AL COMITETULUI DE TERAPII CELULARE MINISTRUL SĂNĂTĂȚII, ROMÂNIA</p>
2017 – PREZENT	<p>SECRETAR AL COMITETULUI DE HEMATOLOGIE MINISTRUL SĂNĂTĂȚII, ROMÂNIA</p>
2017 – PREZENT	<p>ȘEF DE LUCRĂRI – DEPARTAMENTUL DE HEMATOLOGIE UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE “IULIU HAȚIEGANU” CLUJ-NAPOCA, ROMÂNIA</p>
2017 – 2022	<p>MEDIC SPECIALIST HEMATOLOG INSTITUTUL ONCOLOGIC ION CHIRICUȚĂ, CLUJ-NAPOCA, ROMÂNIA</p>
2022 - PREZENT	<p>CERCETĂTOR ȘTIINȚIFIC GRAD I CENTRUL DE CERCETĂRI MEDFUTURE, UMF CLUJ-NAPOCA, ROMÂNIA</p>
2015-2020	<p>CERCETĂTOR ȘTIINȚIFIC GRAD III CENTRUL DE CERCETĂRI PENTRU GENOMICA FUNCȚIONALĂ, BIOMEDICINĂ ȘI MEDICINĂ TRANSLAȚIONALĂ, CLUJ-NAPOCA, ROMÂNIA</p>
2013-2016	<p>MEDIC REZIDENT – HEMATOLOGIE INSTITUTUL ONCOLOGIC ION CHIRICUȚĂ, CLUJ-NAPOCA, ROMÂNIA</p>
2013-2015	<p>CERCETĂTOR ȘTIINȚIFIC CENTRUL DE CERCETĂRI PENTRU GENOMICA FUNCȚIONALĂ, BIOMEDICINĂ ȘI MEDICINĂ TRANSLAȚIONALĂ, CLUJ-NAPOCA, ROMÂNIA</p>
2011-2013	<p>POSTDOCTORAND JOHNS HOPKINS SCHOOL OF MEDICINE, BALTIMORE, MD, USA</p>
2009-2011	<p>ASISTENT CERCETARE – DEPARTAMENTUL DE HISTOLOGIE UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE “IULIU HAȚIEGANU” CLUJ-NAPOCA, ROMÂNIA</p>
2007-2011	<p>ASISTENT CERCETARE – DEPARTAMENTUL DE IMUNOLOGIE</p>

UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE "IULIU HAȚIEGANU" CLUJ-NAPOCA, ROMÂNIA

EDUCAȚIE ȘI FORMARE

SEPTEMBRIE 2018	TRAINING ÎN IMUNOTERAPII PENTRU BOLI HEMATOLOGICE DEPARTAMENTUL DE IMUNOLOGIE, INSTITUTUL ONCOLOGIC NAȚIONAL, TOKYO, JAPONIA
OCTOMBRIE 2017	TRAINING ÎN MANAGEMENTUL COMPLICAȚIILOR POST-TRANSPLANT ALLOGENEIC DE CELULE STEM HEMATOPOIETICE DEPARTAMENTUL DE TRANSPLANT DE CELULE STEM, INSTITUTUL ONCOLOGIC NAȚIONAL, TOKYO, JAPONIA
NOIEMBRIE 2017	TRAINING ÎN TRANSPLANTUL ALLOGENEIC DE CELULE STEM HEMATOPOIETICE PENTRU MALIGNITĂȚI DE CELULE T DEPARTAMENTUL DE TRANSPLANT DE CELULE STEM, INSTITUTUL ONCOLOGIC NAȚIONAL, TOKYO, JAPONIA
2016-2017	TRAINING ÎN CERCETARE CLINICĂ ȘI TRIALURI CLINICE SOCIETATEA EUROPEANĂ DE HEMATOLOGIE
IUNIE-OCTOMBRIE 2015	TRAINING ÎN TRANSPLANTUL HAPLOIDENTIC DE CELULE STEM DEPARTAMENTUL DE TRANSPLANT DE CELULE STEM ȘI TERAPII CELULARE, INSTITUTUL ONCOLOGIC ANDERSON, HOUSTON, STATELE UNITE ALE AMERICII
2013-2016	REZIDENȚIAT INSTITUTUL ONCOLOGIC ION CHIRICUȚĂ, CLUJ-NAPOCA, ROMÂNIA
2011-2013	POSTDOCTORAT ÎN BIOLOGIE TUMORALĂ DEPARTAMENTUL DE MEDICINĂ INTERNĂ, COMPARTIMENTUL DE GASTROENTEROLOGIE ȘI HEMATOLOGIE, THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, BALTIMORE, STATELE UNITE ALE AMERICII
2011-2013	DOCTORAT DEPARTAMENTUL DE IMUNOLOGIE, UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE "IULIU HAȚIEGANU" CLUJ-NAPOCA, ROMÂNIA
2005-2011	STUDENT MEDICINIST UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE "IULIU HAȚIEGANU" CLUJ-NAPOCA, ROMÂNIA
2001-2005	ELEV COLEGIUL NAȚIONAL CALISTRAT HOGAȘ, PIATRA NEAMȚ, ROMÂNIA

COMPETENȚE PERSONALE

 Limba maternă **ROMÂNĂ**

Alte limbi străine cunoscute

	INTELEGERE		VORBIRE		SCRIERE
	Ascultare	Citire	Participare la conversație	Discurs oral	
ENGLEZĂ	C1/2	C1/2	C1/2	C1/2	C1/2
FRANCEZĂ	B1/2	B1/2	B1/2	B1/2	B1/2

 Niveluri: A1/2: Utilizator elementar - B1/2: Utilizator independent - C1/2: Utilizator experimentat
 Cadrul european comun de referință pentru limbi străine

MERITE ÎN DOMENIUL MEDICINII

- Izolarea in vitro a primei linii de celule stem canceroase din România, în martie 2010, ca student în anul IV la medicină (**Tomuleasa C**, Soritau O, Rus-Ciuca D, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestinal Liver Dis. 2010; 19(1):61-7)
- Coautor în lucrări științifice publicate de un laureat de premiu Nobe (Aaron Ciechanover):
 KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma. Sergiu Pasca, Ciprian Tomuleasa, Gabriel Ghiaur, Delia Dima, Vlad Moisoiu, Cristian Berce, Cristina Stefan, **Aaron Ciechanover**, Hermann Einsele. Frontiers in Oncology, 2019, 9:1137.
 Targeting ubiquitination in myeloid malignancies. From basic research to drug discovery in MDS and AML. Rares Drula, Sabina Iluta, Diana Gulei, Delia Dima, Cristina Iuga, Anca Dana Buzoianu, Gabriel Ghiaur, **Aaron Ciechanover**, Ciprian Tomuleasa. Blood Reviews, 2022.
 Insights into the roles of ubiquitin ligase KPC1: from cell cycle control to NF-κB regulator. Diana Gulei, Rares Drula, Gabriel Ghiaur, Anca Dana Buzoianu, Ciprian Tomuleasa, **Aaron Ciechanover**. Cancer Research, 2023.
 The NF-κB subunit generated by KPC1-mediated ubiquitination and proteasomal processing suppresses tumor growth. Yelena Kravtsova-Ivantsiv, Gilad Goldhirsh, Ciprian Tomuleasa, Eli Pikarsky, **Aaron Ciechanover**. Cancer Cell International 2023.
 Proteasome inhibition in combination with immunotherapies: state-of-the-art in multiple myeloma. David Kegyes, Diana Gulei, Rares Drula, Diana Cenariu, Bogdan Tigu, Delia Dima, Alina Tanase, Sorina Badelita, Anca-Dana Buzoianu, Stefan Ciurea, Gabriel Ghiaur, Evangelos Terpos, **Aaron Ciechanover**, Hermann Einsele, Ciprian Tomuleasa. Blood Reviews, 2023.
- Membru al grupului de lucru de diagnostică in vitro al OMS (Geneva, 2020)
- INDEX HIRSCH: **33 (Scopus) ; 41 (Google Scholar)**

MEMBRU ÎN SOCIETĂȚI PROFESIONALE

2022 – PREZENT	Societatea de Oncologie Hematologică
2019 – PREZENT	Societatea Japoneză de Hematologie
2017 – PREZENT	Societatea Română de Hematologie
2016 – PREZENT	Societatea Română de Transplant Medular (Membru Fondator)
2014 – PREZENT	Societatea Europeană de Hematologie
2014 – PREZENT	Societatea Americană de Hematologie
2008 – PREZENT	Societatea Română de Radioterapie și Oncologie Medicală

INFORMATII SUPLIMENTARE
PARTICIPANT ACTIV CU PREZENTAREA ORALĂ SAU POSTER:

- NAȚIONALE: 35
- INTERNAȚIONALE: 41 – Australia (Melbourne), Austria (Vienna), Belgia (Anvers), China (Beijing), Croația (Zagreb), Cipru (Nicosia), Republica Cehă (Brno), Danemarca (Copenhagen), Egipt (Cairo), Franța (Angers, Bordeaux, Champéry, Paris), Germania (Berlin, Jena, Lindau), Grecia (Ioannina), Ungaria (Budapesta, Pécs, Szeged), Islanda (Reykjavik), Italia (Bologna, Milano, Roma, Viareggio), Japonia (Osaka, Tokyo), Lituania (Druskininkai), Moldova (Chișinău), Olanda (Duin et Kruidbergeweg), Polonia (Poznan, Krakow), Portugalia

(Faro), România (București, Cluj-Napoca, Iași, Poiana Brașov, Piatra Neamț, Predeal, Sinaia, Timișoara, Tulcea), Rusia (Moscova), Serbia (Novi Sad), Africa de Sud (Cape Town, Stellenbosch), Spania (Barcelona, Madrid, Sitges, Valencia), Elveția (Geneva), Taiwan (Taipei), Regatul Unit al Marii Britanii (Edinburgh, London), Statele Unite ale Americii (Atlanta, Boston, Baltimore, Honolulu, Houston, Orlando, San Diego, San Francisco)

- **SPEAKER INVITAT:**

- DECEMBRIE 2021– Ohio State University, Columbus, OH, Statele Unite Ale Americii
- MAI 2021 – Reykjavik University, Reykjavik, Islanda
- MARTIE 2018 – University Of Iceland, Reykjavik, Islanda
- OCTOMBRIE 2017 – Osaka International Cancer Center, Osaka, Japonia
- SEPTEMBRIE 2017, OCTOMBRIE 2019 – People’s Liberation Army Navy Hospital, Beijing, China
- FEBRUARIE 2017 – University Of The Western Cape, Cape Town, Africa De Sud
- NOIEMBRIE 2016 – Stellenbosch University, Stellenbosch, Africa De Sud

ORGANIZATOR EVENIMENTE ȘTIINȚIFICE:

NOIEMBRIE 2021	Keynote speaker in hematology series – Prof. Dr. Dieter Hölzer (University of Frankfurt, Germania)
19-20 SEPTEMBRIE 2021	Insights In Hematology, ediția a 5-a - hibrid (președinte congres)
19-20 SEPTEMBRIE 2020	Insights In Hematology, ediția a 5-a - online (președinte congres)
NOIEMBRIE 2019	Keynote speaker in hematology series – Prof. Dr. Gabriel Ghiaur (Johns Hopkins University, Baltimore, MD, Statele Unite ale Americii)
OCTOMBRIE 2019	Keynote speaker in hematology series – Prof. Dr. Erik Aerts (University of Zürich, Zürich, Elveția)
OCTOMBRIE 2019	Keynote speaker in hematology series – Prof. Dr. Hermann Einsele (University of Würzburg, Würzburg, Germania)
IULIE 2019	Keynote speaker in hematology series – Prof. Dr. Anders Tveita (University of Oslo, Oslo, Norway)
12-14 MAI 2019	Insights In Hematology, ediția a 4-a (președinte congres)
DECEMBRIE 2018	Keynote speaker in hematology series – Aaron Ciechanover
9-10 MARTIE 2018	Insights In Hematology, ediția a 3-a (președinte congres)
9 SEPTEMBRIE 2017	Beijing-Cluj Hematology Summit Forum
10-11 MARTIE 2017	Insights In Hematology, ediția a 2-a (președinte congres)
11-12 MARTIE 2016	Insights In Hematology (președinte congres)
11 SEPTEMBRIE 2015	Nanotechnology in leukemia chemotherapy (președinte congres)

EXPERIENȚA EDITORIALĂ:

2021	editor invitat (special issue) – Frontiers in Medicine, IF: 5.091
2020	editor invitat (special issue) – Frontiers in Medicine, IF: 5.091
2019	editor invitat (special issue) – Frontiers in Pharmacology, IF: 3.92
2019 – PREZENT	membru comitet editorial – Annals of Translational Medicine, IF: 3.689
2018 - PREZENT	membru comitet editorial – Journal of Clinical Medicine, IF: 5.688
2018 - PREZENT	membru comitet editorial – Medicine and Pharmacy Reports

GRANTURI DE CERCETARE COORDONATE:

No.	Funding	Projects	Position	Period	Partner
-----	---------	----------	----------	--------	---------

	mechanism				budget (EURO)
1	Grant received after the Romania – European Economic Space (EES) International Research Grant Competition 2014-2016	Nanotechnology approach in Acute Myeloid Leukemia management – Collaboration with Norway (University of Bergen) – acronym: NanoLAM	Grant manager for the partner institution - Ion Chircuta Oncology Institute (Principal investigator – Prof. Andrei Cucuianu, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca). Co-principal investigator: Prof. Emmet McCormack – University of Bergen, Norway	2014-2016	110.000
2	Internal Grant Competition of the Iuliu Hatieganu University of Medicine and Pharmacy, for young researchers, 2014-2015	Cell and molecular mechanisms of primary myelofibrosis	Principal investigator - Iuliu Hatieganu University of Medicine and Pharmacy	2014-2015	8.000
3	Grant received after the Romania–European Economic Space (EES) International Grant Competition 2015-2016	Innovative Nanoparticles-based Chemotherapy for Acute Myeloid Leukemia - Collaboration with Norway (University of Bergen) – acronym: NanoChemotherapy	Principal investigator- Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Emmet McCormack – University of Bergen, Norway	2015-2016	41.000
4	Grant received after the Young Research Team Competition, awarded by the Romanian Research Ministry and Education 2016-2017	Massively parallel high-throughput DNA sequencing for the identification of microRNAs differentially expressed between the metastatic site and the tissue of origin in cancers of unknown primary site	Principal investigator- Iuliu Hatieganu University of Medicine and Pharmacy	2016-2017	125.000
5	Internal Grant Competition of the Iuliu Hatieganu University of Medicine and Pharmacy, for medical students, 2015-2016	A synthetic lethality approach in the acute myeloid leukaemia chemotherapy: PARP inhibitors plus anthracycline plus decitabine vs anthracycline plus decitabine –in vitro efficacy testing	Grant mentor for Grigore Gafencu	2015-2016	2.000
6	Internal Grant	The efficacy of pirfenidone in	Grant mentor for	2016-	2.000

	Competition of the Iuliu Hatieganu University of Medicine and Pharmacy, for medical students, 2015-2016	primary myelofibrosis	Sonia Selicean	2017	
7	Grant resgna;ceived after the Romania - P.R. China International Bilateral Collaboration competition 2016-2017	Invasive biomarkers for graft versus host disease following bone marrow hematopoietic stem cell transplantation	Principal investigator- Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Jianlian Shen – Navy General Hospital, Beijing, China	2016-2017	9.533
8	Grant received after the FDI competition of the National Council for the Financing of University Education 2017	Modern training for healthcare professionals affiliated to the departments of hematology, oncology and bone marrow transplantation	Principal investigator- Iuliu Hatieganu University of Medicine and Pharmacy	2017	43.826
9	Grant received after the FDI competition of the National Council for the Financing of University Education 2018	Correlation of the educational curricula in molecular medicine and translational onco-hematology with the European workforce demand	Principal investigator- Iuliu Hatieganu University of Medicine and Pharmacy	2018	38.922
10	Grant received from the National Research Ministry for Frontiers Research 2017-2022	Multifunctional magnetoplasmonic nanoparticles for point of care applications in acute myeloid leukemia, acronym: NanoTEX	Grant manager for Ion Chiricuta Oncology Institute. (Principal investigator: Prof. Emil Burzo, Babes Bolyai University Cluj Napoca, Romania)	2018-2022	180.000 (total grant value – 1.800.000)
11	Invited Professor 2018 Grant – Gabriel Ghiaur, Johns Hopkins University School of Medicine, from the National Research Ministry	Invited Professor Grant – Gabriel Ghiaur, Johns Hopkins University School of Medicine.	Principal investigator, for the Iuliu Hatieganu University of Medicine and Pharmacy.	2018	2.619
12	Grant received after the Romania - P.R. China International Bilateral Collaboration competition 2018-2019	Experimental Immunotherapy for hematological malignancies	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Liren Qian,	2018 - 2019	8.609

			Navy General Hospital, Beijing, China		
13.	Grant received after the FDI competition of the National Council for the Financing of University Education 2019	Increase of the competitiveness of medical education by correlating the curricula to Anglo-Saxon standards	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy	2019	41.916
14.	Grant received after the Romania–European Economic Space (EES) International Grant Competition – Collaboration with Iceland; 2020-2022	HE-RO-IS strategic collaboration in hematology – Iceland collaboration (Reykjavik University) – Acronym: HERO	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Olafur Eysteinn Sigurjonsson, Reykjavik University, Iceland	2020 - 2021	144.153
15.	Novo Nordisk Haemophilia Foundation International Grant 2020-2022	Strengthen haemophilia care in the north and establish a national registry in Romania – Romania 3	Principal investigator, Romanian Hematology Society	2020 - 2021	81.903
16.	Grant received from the National Research Ministry for Postdoctoral Research 2020-2022	Evaluation of the effect of human chorionic gonadotrophin in stem cell transplantation as a new method of pretransplant mobilization	Grant mentor for Andrei Cismaru - MD, PhD, Iuliu Hatieganu University of Medicine and Pharmacy	2020 - 2022	51.667
17.	Grant received from the National Research Ministry for Postdoctoral Research 2020-2022	New generation preclinical model for evaluating the therapeutic role of microRNA-505-5p for metastasis limitation in melanoma	Grant mentor for Diana Gulei - PhD, Iuliu Hatieganu University of Medicine and Pharmacy	2020 - 2022	51.667
18.	Grant received from the National Research Ministry for Young Research Teams 2020-2022	Supporting a team of young researchers in creating an independent research program based on the use of the Sleeping Beauty protocol for developing CAR T cells – Acronym: SEATTLE	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy	2020 - 2022	93.001
19.	Grant received after the Romania – Wallonia/Belgium International Bilateral Collaboration competition 2020-2022	Consolidation of the Wallonia-Romania collaboration for setting of new standard operation procedures (SOP) in immunotherapy	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Jo Caers,	2021-2022	10.561

			University of Liege, Belgium		
20.	Grant received from the National Research Ministry for Exploratory Research 2020-2023	Harnessing the ubiquitin-proteasome system (UPS) to suppress tumor's growth via manipulating generation of NF-kB – Acronym: ROME	Co-principal investigator , Iuliu Hatieganu University of Medicine and Pharmacy. Principal investigator: Prof. Aaron Ciechanover – Nobel Prize in Chemistry 2004	2021-2024	250.000
21.	Grant received from the National Research Ministry for Exploratory Research 2020-2023	The role of stromal CYP26 in retinoid homeostasis in the context of myelodysplastic syndromes pathogenesis and response to treatment Acronym: LONDON	Co-principal investigator , Iuliu Hatieganu University of Medicine and Pharmacy. Principal investigator: Prof. Gabriel Ghiaur	2021 - 2024	250.000
22.	Novo Nordisk Haemophilia Foundation International Grant 2022-2024	Strengthen haemophilia care in the north-eastern part of Romania and in Moldova and establish a registry in Moldova – Romania 4	Principal investigator , Romanian Hematology Society	2022 - 2024	102.779
23.	Grant received from the National Health Ministry, for providing outreach healthcare services to vulnerable population from isolated areas 2022-2023	Sequencing as standard-of-care in diagnosis of hemophilia and rare coagulation disorders in Romania	Principal investigator , Iuliu Hatieganu University of Medicine and Pharmacy. Grant director: Romanian Hemophilia Association (Mr. Daniel Andrei)	2022 - 2023	222.222
24.	Grant received from the Romanian Academy of Science	Mathematical model for clonal hematopoiesis	Principal investigator , Iuliu Hatieganu University of Medicine and Pharmacy.	2023-2024	10.000
25.	Grant received from the European Hematology Association	CAR NK-cells for tumor-associated macrophage immunomodulation – a new era of immunotherapy	Principal investigator , Iuliu Hatieganu University of Medicine and Pharmacy.	2024	20.000
26.	Grant received from the Romanian Government, National Plan for Resilience (PNRR)	Creating a Research Group of Excellence to develop cell and immune therapy technology to target the tumor microenvironment	Co-principal investigator , Iuliu Hatieganu University of Medicine and Pharmacy.	2024-2026	996.125

			Principal investigator: Prof. Hermann Einsele		
27	Grant received from the National Research Ministry for bilateral research with Moldova	Collaborative RO MD research on diagnosis, prognosis and treatment strategies for patients with HIV (+) DLBCL	Principal investigator, Luliu Hatieganu University of Medicine and Pharmacy.	2024 - 2025	142.835
28.	Grant received from the National Research Ministry – Henri Coanda Award	Genomic, transcriptomic and metabolomic evaluation of resistance to venetoclax in acute myeloid leukemia	Grant mentor for David Keyes - MD, Luliu Hatieganu University of Medicine and Pharmacy	2024	20.000
29.	Grant received after the Romania – Wallonia/Belgium International Bilateral Collaboration competition 2024-2025	RNA methylation as a prognostic factor in myelodysplastic syndromes treated with azacytidine	Principal investigator, Luliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Stefan Constantinescu, Catholic University of Louvain, Belgium	2024 - 2025	10.000
30.	Grant received from the European Commission – the MSCA Doctoral Network	Advancing in the challenge of improving Lymphoma and Leukemia Survival	Grant Manager for the Luliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Laura Belver, Josep Carreras Leukemia Institute, Barcelona, Spain	2025-2028	246.245 (out of 4.251.582)
Total amount of continuous funding between 2014 - present					3.316.583 EURO

TRIALURI CLINICE – EXPERIENTA:

No.	Disease	Title	Sponsor / International investigator / Period	Role in the study
1.	Leucemie acuta mieloida FLT3-pozitiva, prima linie	Phase III clinical trial investigating quizartinib plus standard chemotherapy versus	Daiichi-Sankyo, 2018-2020	Co-investigator al Institutului Oncologic Ion Chiricuta

		standard chemotherapy , for patients with therapy-naïve FLT3-IDT positive acute myeloid leukemia		Cluj Napoca (Principal investigator: Dr. Delia Dima)
2.	Limfoame cu celule T, prima linie	Prospective, longitudinal, multinational registry of patients with newly diagnosed peripheral T cell lymphoma	Associazione Angela Serra per la Ricerca sul Cancro Centro Oncologico Modenese - Medical Oncology, School of Medicine University of Modena and Reggio Emilia Modena, Italy, 2018 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
3.	Hemoglobinurie paroxistica nocturna, prima linie	A phase III randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and eculizumab in subjects with paroxysmal nocturnal hemoglobinuria	Samsung Bioepis, 2019-2022	Co-investigator al Institutului Oncologic Ion Chiricuta Cluj Napoca (Principal investigator: Dr. Delia Dima)
4.	Leucemie acuta mieloida, pacienti ineligibili de tratament intensiv	Real world treatment patterns and clinical outcomes in unfit AML patients receiving first line systemic treatment or best supportive care (study H19-743)	Abbvie, 2019-2020	Investigator Principal al Institutului Oncologic Ion Chiricuta
5.	Limfom cu celule de manta, pacienti ineligibili de tratament intensiv	A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation	BeiGene, 2021 - present	Co-investigator for Ion Chiricuta Oncology Institute Cluj Napoca (Principal investigator: Dr. Delia Dima)

6.	Mielofibroza primara, prima linie	A Phase 3 Randomized, double-blind, active-control study of CPI-0610 and ruxolitinib versus placebo and ruxolitinib in JAKi treatment naïve MF patients (MANIFEST-2)	Constellation Pharmaceuticals, 2021 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
7.	Afectiuni hemato-oncologice	Evaluation of the safety of pegfilgrastim in the primary prophylaxis of febrile neutropenia in patients with myelosuppressive chemotherapy	Totem Communication, 2022 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
8.	Hemofilie A	A multinational, open-label, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors (FRONTIER-2)	Novo Nordisk Pharmaceuticals, 2022 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta Institute Cluj Napoca
9.	Limfom follicular, refractar / recidivat	Towards personalized medicine for refractory/relapsed Follicular Lymphoma patients: the Cantera/Lupiae registry	European Hematology Association (EHA) Lymphoma Group, 2022 – present	Investigator Principal al Institutului Oncologic Ion Chiricuta
10.	Mielofibroza primara	A multi-country, real-world study to explore treatment patterns, effectiveness and healthcare resource utilization for patients diagnosed with myelofibrosis through chart review (METER)	Abbvie, 2022 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
11.	Policitemia vera	A Prospective, Multicenter, Non-interventional, Observational, Post-authorization Safety Study of Ropeginterferon alfa-2b in Polycythemia Vera Patients (Besremi-PASS)	AOP Orphan, 2022 - present	Investigator Principal al Institutului Oncologic Ion Chiricuta
12.	Mielom multiplu refractar ./ recidivat	A phase 3, two-stage, randomized, multicenter, open label study comparing CC-	Bristol Myers Squibb, 2022-present	Investigator Principal al Institutului

		92480, bortezomib and dexamethasone (480 Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma.		Oncologic ion Chiricuta
13.	Limfom follicular si limfom de zona marginala, refractar sau recidivat	A retrospective multicenter, non-interventional study to generate a real-world comparator cohort in adult patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma	Bristol Myers Squibb, 2022-present	Investigator Principal al Institutului Oncologic ion Chiricuta

CĂRȚI PUBLICATE:

1. NANOPHARMACOLOGY IN LEUKEMIA CHEMOTHERAPY. Andrei Cucuianu, **Ciprian Tomuleasa**, Anca Bojan, Cristian Berce, Simion Astilean, Emmet McCormack. Editura Cartea Ardeleana, Cluj Napoca, 2015. ISBN 978-606-8699-74-5.
2. CHIMIOTERAPIE HEMATOLOGICA. **Ciprian Tomuleasa**, Mariana Patiu, Anca Bojan, Mihnea Zdrengea, Cristian Berce, Ioana Frinc, Bobe Petrushev, Delia Dima, George Calin, Alina Tanase, Stefan Ciurea. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-30-7.
3. HEMATOLOGIA IN IMAGINI. Delia Dima, Mariana Patiu, Anca Bojan, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-69-7.
4. LEUCEMIA MIELOIDA CRONICA. DE LA TERAPIA CU INHIBITORI DE TIROZIN KINAZE LA TRANSPLANT. **Ciprian Tomuleasa**, Delia Dima, Adrian Trifa. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-98-7.
5. NEOPLASMELE MIELOPROLIFERATIVE. Cristina Bagacean, Iulia Berceanu, Delia Dima, Bogdan Fetica, Jean-Cristophe Ianotto, Mariana Patiu, Adrian Tempescul, **Ciprian Tomuleasa**, Adrian Trifa, Mihnea Zdrengea. Sub redactia Mihnea Zdrengea. Editura Casa Cartii de Stiinta, Cluj Napoca, 2017. ISBN 978-606-17-1135-2.
6. GHID DE TRANSPLANT MEDULAR. Alina Tanase, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca, 2017.

CAPITOLE DE CĂRȚI PUBLICATE:

• **CĂRȚI INTERNAȚIONALE:**

1. TYPES OF RESEARCH DESIGNS. Fedor Moissenko, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. In "CANCER RESEARCH AND CLINICAL TRIALS IN DEVELOPING COUNTRIES". Springer Science Books, ISBN 978-3-319-18443-2, Cape Town, South Africa 2016.
2. THEORETICAL MODELS OF HEMATOPOIETIC CELL DYNAMICS RELATED TO BONE MARROW TRANSPLANTATION. Radu Precup, Delia Dima, **Ciprian Tomuleasa**, Marcel Adrian Serban, Lorand Parajdi. In "Frontiers in Stem Cell and Regenerative Medicine Research". Betham Science Publishers, 2017.
3. NON-CODING RNAS IN LUNG CANCER ANGIOGENESIS. Cornelia Braicu, **Ciprian Tomuleasa**, Diana Gulej, George Adrian Calin, Ioana Berindan-Neagoe. In "Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy", book edited by Dan Simionescu and Agneta Simionescu, ISBN 978-953-51-3024-6, Print ISBN 978-953-51-3023-9, 2017.
4. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Mihnea Zdrengea, Delia Dima, **Ciprian Tomuleasa**, Horia Bumbea, Cristina Bagacean. In " New Approaches to the Management of Primary and Secondary CNS Tumors is published " Intech, ISBN 978-953-51-3052-9, 2017.

5. THE USEFULNESS OF BIOMARKERS FOR DIAGNOSIS. Patric Teodorescu, Sergiu Pasca, **Ciprian Tomuleasa**. In "Pineal region lesions. Management strategies and controversial issues. Springer – Zurich, 2020, ISBN 978-3-030-50912-5.

- **CĂRȚI NAȚIONALE:**

1. CORELATII CLINICO-GENETICO-MOLECULARE IN ONCO-HEMATOLOGIE. **Ciprian Tomuleasa**, Delia Dima. In "PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE". Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.
2. ROLUL PROGNOSTIC AL CITOGENETICII SI AL BIOLOGIEI MOLECULARE IN TRANSPLANTUL AUTOLOG DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Delia Dima, Alina Tanase. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.
3. REGIMURI DE CONDITIONARE. Alina Tanase, **Ciprian Tomuleasa**. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.
4. EVALUAREA CARDIACA PENTRU TRANSPLANTUL DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Sergiu Pasca, Anca Bojan, Delia Dima. In "MANUAL DE CARDIOONCOLOGIE". Cristina Vlad, Dan Radulescu, Simona Dragan, Claudia Burz. Editura Medicala Universitara Iuliu Hatieganu 2020.

ARTICOLE PUBLICATE: 235 ARTICOLE ISI IN EXTENSO

23.07.2025